Just before the 23andMe SPAC deal closed, the stock belonging to its merger ... giving investors the impression it is a ...

Me collected information from survey questions about personal health and beyond, such as drinking habits and risk tolerance.

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

Me is pursuing a sale after filing for bankruptcy, leading many customers to look into deleting their data from the company.

The direct-to-consumer DNA testing service 23andMe filed for bankruptcy earlier this month, putting millions of customers' ...

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data breach that damaged its reputation.

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...

GlaxoSmithKline also made a $300 million equity investment in 23andMe. When 23andMe went public ... if it shows that they have or are at high risk of developing a genetic disease or disorder.

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...